163 related articles for article (PubMed ID: 30952619)
1. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S; Popovic M; de la Rochefordiere A; Girard E; Dureau S; Mandic A; Koprivsek K; Samet N; Craina M; Margan M; Samuels S; Zijlmans H; Kenter G; Hillemanns P; Dema S; Dema A; Malenkovic G; Djuran B; Floquet A; Garbay D; Guyon F; Colombo PE; Fabbro M; Kerr C; Ngo C; Lecuru F; Campo ERD; Coutant C; Marchal F; Mesgouez-Nebout N; Fourchotte V; Feron JG; Morice P; Deutsch E; Wimberger P; Classe JM; Gleeson N; von der Leyen H; Minsat M; Dubot C; Gestraud P; Kereszt A; Nagy I; Balint B; Berns E; Jordanova E; Saint-Jorre N; Savignoni A; Servant N; Hupe P; de Koning L; Fumoleau P; Rouzier R; Kamal M
EBioMedicine; 2019 May; 43():253-260. PubMed ID: 30952619
[TBL] [Abstract][Full Text] [Related]
2. Genetic markers and phosphoprotein forms of beta-catenin pβ-Cat552 and pβ-Cat675 are prognostic biomarkers of cervical cancer.
Scholl SM; Beal J; de Koning L; Girard E; Popovic M; de la Rochefordière A; Lecuru F; Fourchotte V; Ngo C; Floquet A; Berns EM; Kenter G; Gestraud P; von der Leyen H; Lecerf C; Puard V; Roman SR; Latouche A; Kereszt A; Balint B; Rouzier R; Kamal M
EBioMedicine; 2020 Nov; 61():103049. PubMed ID: 33096476
[TBL] [Abstract][Full Text] [Related]
3. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy.
Zammataro L; Lopez S; Bellone S; Pettinella F; Bonazzoli E; Perrone E; Zhao S; Menderes G; Altwerger G; Han C; Zeybek B; Bianchi A; Manzano A; Manara P; Cocco E; Buza N; Hui P; Wong S; Ravaggi A; Bignotti E; Romani C; Todeschini P; Zanotti L; Odicino F; Pecorelli S; Donzelli C; Ardighieri L; Angioli R; Raspagliesi F; Scambia G; Choi J; Dong W; Bilguvar K; Alexandrov LB; Silasi DA; Huang GS; Ratner E; Azodi M; Schwartz PE; Pirazzoli V; Stiegler AL; Boggon TJ; Lifton RP; Schlessinger J; Santin AD
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22730-22736. PubMed ID: 31624127
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
5. From prospective biobanking to precision medicine: BIO-RAIDs - an EU study protocol in cervical cancer.
Ngo C; Samuels S; Bagrintseva K; Slocker A; Hupé P; Kenter G; Popovic M; Samet N; Tresca P; von der Leyen H; Deutsch E; Rouzier R; Belin L; Kamal M; Scholl S;
BMC Cancer; 2015 Nov; 15():842. PubMed ID: 26531748
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
[TBL] [Abstract][Full Text] [Related]
7. Efficient mutation screening for cervical cancers from circulating tumor DNA in blood.
Lee SY; Chae DK; Lee SH; Lim Y; An J; Chae CH; Kim BC; Bhak J; Bolser D; Cho DH
BMC Cancer; 2020 Jul; 20(1):694. PubMed ID: 32718341
[TBL] [Abstract][Full Text] [Related]
8. RAIDS atlas of significant genetic and protein biomarkers in cervical cancer.
Scholl S; Roufai DB; Chérif LL; Kamal M
J Gynecol Oncol; 2023 Sep; 34(5):e74. PubMed ID: 37668079
[TBL] [Abstract][Full Text] [Related]
9. Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial.
Huang X; He M; Peng H; Tong C; Liu Z; Zhang X; Shao Y; Zhu D; Zhang J; Yin JC; Yang F; Lan C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34011535
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
12. The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix.
Pei X; Xiang L; Chen W; Jiang W; Yin L; Shen X; Zhou X; Yang H
Gynecol Oncol; 2021 Jun; 161(3):779-786. PubMed ID: 33888337
[TBL] [Abstract][Full Text] [Related]
13. Mutational profiles of marker genes of cervical carcinoma in Bangladeshi patients.
Sharmin S; Zohura FT; Islam MS; Shimonty A; Khan MA; Parveen R; Sharmin F; Ahsan CR; Islam ABMMK; Yasmin M
BMC Cancer; 2021 Mar; 21(1):289. PubMed ID: 33736612
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.
Yokota T; Serizawa M; Hosokawa A; Kusafuka K; Mori K; Sugiyama T; Tsubosa Y; Koh Y
BMC Cancer; 2018 Aug; 18(1):826. PubMed ID: 30115035
[TBL] [Abstract][Full Text] [Related]
15. Genomic landscape, immune characteristics and prognostic mutation signature of cervical cancer in China.
Liu J; Li Z; Lu T; Pan J; Li L; Song Y; Hu D; Zhuo Y; Chen Y; Xu Q
BMC Med Genomics; 2022 Nov; 15(1):231. PubMed ID: 36333792
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the Genomic Landscape in Cervical Cancer by Next Generation Sequencing.
Qiu L; Feng H; Yu H; Li M; You Y; Zhu S; Yang W; Jiang H; Wu X
Genes (Basel); 2022 Jan; 13(2):. PubMed ID: 35205332
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic Alteration by DNA Methylation of ESR1, MYOD1 and hTERT Gene Promoters is Useful for Prediction of Response in Patients of Locally Advanced Invasive Cervical Carcinoma Treated by Chemoradiation.
Sood S; Patel FD; Ghosh S; Arora A; Dhaliwal LK; Srinivasan R
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):720-7. PubMed ID: 26344356
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
Chung TKH; Cheung TH; Yim SF; Yu MY; Chiu RWK; Lo KWK; Lee IPC; Wong RRY; Lau KKM; Wang VW; Worley MJ; Elias KM; Fiascone SJ; Smith DI; Berkowitz RS; Wong YF
Gynecol Oncol; 2017 Aug; 146(2):334-339. PubMed ID: 28587748
[TBL] [Abstract][Full Text] [Related]
19. Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation.
Wei Y; Wei C; Chen L; Liu N; Ou Q; Yin JC; Pang J; Fang Z; Wu X; Wang X; Mu D; Shao Y; Yu J; Yuan S
Cancer Res Treat; 2022 Oct; 54(4):1209-1218. PubMed ID: 35038823
[TBL] [Abstract][Full Text] [Related]
20. Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets.
Friedman CF; Ravichandran V; Miller K; Vanderbilt C; Zhou Q; Iasonos A; Vivek M; Mishra P; Leitao MM; Broach V; Sonoda Y; Kyi C; Zamarin D; O'Cearbhaill RE; Konner J; Berger MF; Weigelt B; Momeni Boroujeni A; Park KJ; Aghajanian C; Solit DB; Donoghue MTA
Clin Cancer Res; 2023 Nov; 29(22):4660-4668. PubMed ID: 37643132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
